GW&K Investment Management LLC Sells 48,596 Shares of ICU Medical, Incorporated (NASDAQ:ICUI)

GW&K Investment Management LLC lessened its holdings in shares of ICU Medical, Incorporated (NASDAQ:ICUI) by 12.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 347,480 shares of the medical instruments supplier’s stock after selling 48,596 shares during the quarter. ICU Medical comprises 0.8% of GW&K Investment Management LLC’s portfolio, making the stock its 25th biggest holding. GW&K Investment Management LLC owned 1.68% of ICU Medical worth $55,457,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of ICUI. Price T Rowe Associates Inc. MD raised its stake in ICU Medical by 22.6% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 3,478,883 shares of the medical instruments supplier’s stock valued at $876,365,000 after purchasing an additional 640,425 shares during the period. Findlay Park Partners LLP bought a new stake in ICU Medical during the 2nd quarter valued at approximately $75,573,000. Janus Henderson Group PLC raised its stake in ICU Medical by 5.2% during the 2nd quarter. Janus Henderson Group PLC now owns 2,825,836 shares of the medical instruments supplier’s stock valued at $711,856,000 after purchasing an additional 140,123 shares during the period. Wells Fargo & Company MN raised its stake in ICU Medical by 41.5% during the 2nd quarter. Wells Fargo & Company MN now owns 418,889 shares of the medical instruments supplier’s stock valued at $105,522,000 after purchasing an additional 122,856 shares during the period. Finally, Invesco Ltd. raised its stake in ICU Medical by 28.1% during the 2nd quarter. Invesco Ltd. now owns 428,233 shares of the medical instruments supplier’s stock valued at $107,876,000 after purchasing an additional 93,904 shares during the period. 93.60% of the stock is currently owned by institutional investors.

In other news, Director Robert S. Swinney sold 373 shares of the business’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $153.49, for a total value of $57,251.77. Following the completion of the transaction, the director now directly owns 18,845 shares of the company’s stock, valued at approximately $2,892,519.05. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Robert S. Swinney sold 2,078 shares of the business’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $165.18, for a total value of $343,244.04. Following the completion of the transaction, the director now directly owns 17,345 shares of the company’s stock, valued at $2,865,047.10. The disclosure for this sale can be found here. Over the last three months, insiders sold 5,451 shares of company stock valued at $862,736. Corporate insiders own 11.40% of the company’s stock.

A number of analysts have issued reports on ICUI shares. TheStreet downgraded ICU Medical from a “b-” rating to a “c+” rating in a research note on Monday, August 12th. ValuEngine raised ICU Medical from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. BidaskClub raised ICU Medical from a “sell” rating to a “hold” rating in a research note on Friday, October 25th. Zacks Investment Research downgraded ICU Medical from a “hold” rating to a “sell” rating in a research note on Wednesday, August 14th. Finally, Raymond James set a $185.00 price objective on ICU Medical and gave the stock a “buy” rating in a research note on Friday, September 6th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $233.00.

NASDAQ:ICUI traded up $1.50 during trading hours on Friday, reaching $167.21. The stock had a trading volume of 101,800 shares, compared to its average volume of 198,185. The stock has a market capitalization of $3.46 billion, a PE ratio of 21.69 and a beta of 0.91. ICU Medical, Incorporated has a 52 week low of $148.89 and a 52 week high of $259.72. The company has a 50 day moving average price of $158.57 and a two-hundred day moving average price of $202.51.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.99 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.86 by $0.13. The firm had revenue of $312.30 million during the quarter, compared to analyst estimates of $315.47 million. ICU Medical had a return on equity of 12.41% and a net margin of 3.56%. The business’s revenue for the quarter was down 13.4% compared to the same quarter last year. During the same period in the previous year, the company posted $2.69 EPS. Sell-side analysts anticipate that ICU Medical, Incorporated will post 7.21 EPS for the current fiscal year.

About ICU Medical

ICU Medical, Inc develops, manufactures, and sells medical devices used in vascular therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein.

Read More: How to Use the New Google Finance Tool

Want to see what other hedge funds are holding ICUI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ICU Medical, Incorporated (NASDAQ:ICUI).

Institutional Ownership by Quarter for ICU Medical (NASDAQ:ICUI)

Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.